Medication info

Linagliptin Metformin Tablets 2.5/1000 mg

Prescription medicationOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Light pink, double-convex, oval film-coated tablet
Packaging
60 tablets (10 tablets/PTP packaging x 6 units)
Approval status
Active

MFDS item code 201801859 · Approved 2018.04.30

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose for each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from concomitant linagliptin and metformin therapy: Patients switching from concomitant linagliptin and metformin therapy to this medicine should start at their current doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients with inadequate glycemic control on concomitant insulin and metformin therapy: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Is Contraindicated).

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood glucose control
View approved original text

This medication is used in conjunction with dietary and exercise therapy to improve blood glucose control in patients with type 2 diabetes. It may be administered when previous treatment with diabetes medications has not been received, or when adequate blood glucose control is not achieved with monotherapy. Additionally, it is used when blood glucose control is insufficient with either monotherapy using metformin or combination therapy with other medications (such as sulfonylureas, insulin, empagliflozin, etc.). This medication effectively regulates blood glucose by replacing or complementing various combination therapies. Therefore, it is an important therapeutic agent that helps in controlling blood glucose levels in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose for each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from concomitant linagliptin and metformin therapy: Patients switching from concomitant linagliptin and metformin therapy to this medicine should start at their current doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients with inadequate glycemic control on concomitant insulin and metformin therapy: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Is Contraindicated).

Precautions

This medication is used to treat type 2 diabetes and helps to control blood glucose levels. This medication may cause serious side effects such as lactic acidosis, so it should not be used in patients with poor kidney function, heart disease, or liver dysfunction. In particular, patients with an allergy to any of the components included in this medication or those with type 1 diabetes, pregnant or breastfeeding women should not take it. Due to the risk of hypoglycemia, caution is required when using this medication with insulin or sulfonylureas, and doses of other medications may be adjusted as necessary. If kidney function is impaired, it is essential to check kidney function before using this medicine and monitor it regularly. This medication should be temporarily discontinued during surgery or radiological examinations, and it can be restarted after kidney function has recovered. Skin conditions like acute pancreatitis or bullous pemphigoid may occur, and any abdominal pain or skin abnormalities during use should be reported to a doctor immediately. Gastrointestinal disturbances such as diarrhea, abdominal pain, nausea, and vomiting may occur during the use of this medication, but most improve naturally over time. As vitamin B12 levels may decrease, regular blood tests are recommended during long-term use to check levels. This medication may interact with other drugs, so inform your doctor or pharmacist of any other medications you are taking. Women who are pregnant or planning to become pregnant should avoid taking this medication and use other treatments for blood glucose control. Elderly patients should have their kidney function checked frequently, as decreased kidney function is common, and it is advisable to start with the lowest dose. It is recommended not to use this medication in children under 10 years of age, as safety and efficacy have not been established. In case of overdose, serious side effects such as lactic acidosis may occur, so the dosage must be strictly adhered to, and if any unusual symptoms appear, immediate medical attention should be sought. This medication should be stored in a cool, dry place away from moisture and direct sunlight, out of reach of children.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • dysgeusia
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 101 more
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • elevated lipase
  • elevated amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficient vitamin B12
  • cheilitis
  • stomatitis
  • epigastric pain
  • dyspepsia
  • gastrointestinal disorders
  • irritable bowel syndrome
  • colitis
  • abdominal discomfort
  • enterocolitis
  • dysphagia
  • gastric ulcer
  • gum bleeding
  • intestinal obstruction
  • tooth loss
  • hemorrhoids
  • lower abdominal pain
  • gastritis
  • gastroesophageal reflux disease
  • gastroenteritis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • herpes zoster
  • cystitis
  • cerebral infarction
  • speech disorders
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • dizziness
  • anxiety
  • affective disorders
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • pruritus
  • hypertension
  • benign prostatic hyperplasia
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • stomatitis
  • mediastinitis
  • rhinitis
  • delirium
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture and should be stored in a tightly closed container. The recommended storage temperature is between 1 to 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication.

Appearance and packaging

Appearance

Light pink, double-convex, oval film-coated tablet

Package unit

60 tablets (10 tablets/PTP packaging x 6 units)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.